---
title: "美股夜盘开盘异动：叁腾科技夜盘涨 10.27% 资金活跃波动加剧"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300233643.md"
description: "Trident Digital Tech - B 夜盘涨 10.27%；Mint Incorporation 夜盘涨 29.67%；Adicet Bio 夜盘涨 13.97%；MagnaChip 半导体夜盘涨 13.94%。"
datetime: "2026-09-28T00:11:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300233643.md)
  - [en](https://longbridge.com/en/news/300233643.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300233643.md)
generator: "portal-rs"
---

# 美股夜盘开盘异动：叁腾科技夜盘涨 10.27% 资金活跃波动加剧

**美股夜盘开盘异动**  
Trident Digital Tech - B，夜盘涨 10.27%，近期无重要新闻。交易活跃，资金流向明显，考虑到板块和行业趋势，该股显示出明显的波动性，具体原因需要进一步观察。  

**美股夜盘涨幅前列股票**  
Mint Incorporation，夜盘涨 29.67%，近期无重要新闻。交易活跃，资金流向明显，考虑到板块和行业趋势，该股显示出明显的波动性，具体原因需要进一步观察。  

Adicet Bio 夜盘涨 13.97%。基于近期关键新闻：  

1\. 9 月 26 日，Adicet Bio 宣布将在 9 月 28 日举行网络直播，披露其在系统性红斑狼疮中的一期数据。此举引发市场对其在自身免疫疾病领域扩展的期待，推动股价上涨。  

2\. 9 月 25 日，Adicet Bio 的异体 CAR-T 疗法被认为具有降低成本和提高可及性的潜力，这种技术的市场前景被投资者看好，进一步提升了公司估值。  

3\. 9 月 25 日，CAR-T 疗法的高定价和强劲收入潜力吸引了投资者的关注，尽管存在监管和制造风险，但其长期增长前景被市场看好。生物科技行业近期表现活跃，资金流入明显。  

MagnaChip 半导体，夜盘涨 13.94%，近期无重要新闻。交易活跃，资金流向明显，考虑到板块和行业趋势，该股显示出明显的波动性，具体原因需要进一步观察。

### Related Stocks

- [TDTH.US](https://longbridge.com/en/quote/TDTH.US.md)
- [MIMI.US](https://longbridge.com/en/quote/MIMI.US.md)
- [ACET.US](https://longbridge.com/en/quote/ACET.US.md)
- [MX.US](https://longbridge.com/en/quote/MX.US.md)

## Related News & Research

- [Trident Expects Sikaflow Revenue of About USD 14 Million by Year-End](https://longbridge.com/en/news/303391245.md)
- [Trident Digital Tech raises USD 8 million in private placement of Class B shares](https://longbridge.com/en/news/300436859.md)
- [Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade](https://longbridge.com/en/news/303771913.md)
- [Invesco QQQ $QQQ Position Decreased by Kelsey Financial LLC](https://longbridge.com/en/news/303727638.md)
- [After Intel's historic stock drop, analysts say there's no reason to buy the dip](https://longbridge.com/en/news/303782727.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**